Labcorp Holdings Inc
BMV:LH
Labcorp Holdings Inc
Labcorp Holdings Inc is a US-based company operating in Health Care Providers & Services industry. The company is headquartered in Burlington, North Carolina and currently employs 67,000 full-time employees. Labcorp Holdings Inc. provides comprehensive laboratory services that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. By leveraging its unparalleled diagnostics and drug development capabilities, the Company provides insights and accelerates innovations to improve health and improve lives. The firm operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The Biopharma Laboratory Services segment consists of early development research laboratories and central laboratory services. The firm serves clients in more than 100 countries.
Labcorp Holdings Inc is a US-based company operating in Health Care Providers & Services industry. The company is headquartered in Burlington, North Carolina and currently employs 67,000 full-time employees. Labcorp Holdings Inc. provides comprehensive laboratory services that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. By leveraging its unparalleled diagnostics and drug development capabilities, the Company provides insights and accelerates innovations to improve health and improve lives. The firm operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The Biopharma Laboratory Services segment consists of early development research laboratories and central laboratory services. The firm serves clients in more than 100 countries.
Strong 2025 Performance: Labcorp delivered over 7% revenue growth, 13% adjusted EPS growth, and margin expansion of more than 50 basis points for the year.
Q4 Results: Fourth quarter revenue grew 5.6% to $3.5 billion, with margins up 120 basis points and adjusted EPS up 18%.
2026 Guidance: Management expects 2026 revenue growth of 4.7% to 6%, midpoint 5.4%, and adjusted EPS growth of about 9%.
Margin Expansion: Both segments contributed to margin improvements in 2025; further meaningful margin expansion is expected in 2026, with BLS margins set to improve more than Diagnostics.
Acquisitions & Pipeline: Multiple acquisitions were completed, with a robust ongoing pipeline and $800 million in share repurchase authorization.
Specialty & Consumer Testing: Esoteric and specialty testing saw double-digit growth; consumer health offerings (Labcorp OnDemand) continued to expand.
Early Development Actions: Early development revenue declined but is being actively streamlined, with $50 million in revenue expected to be consolidated or divested, improving segment profitability.
PAMA Delay: The delay in PAMA through the end of 2026 removes a near-term headwind, but management continues to advocate for permanent reform.
